Thomas Hambrock, et al. Magnetic Resonance Imaging Guided Prostate Biopsy in Men With Repeat Negative Biopsies and Increased Prostate Specific Antigen From the Departments of Radiology and Urology (DMS, IMvO, JAW), University Medical Centre St. Radboud, Nijmegen, The Netherlands. The Journal of Urology, Vol. 183, pp. 520-528, February 2010.

Thomas Hambrock, et al. Correlation of apparent diffusion coefficient values at 3T MRI with prostate cancer Gleason grade in the peripheral zone. Data Presented at the Annual Meeting of the European Congress of Radiology on March 10, 2010.

Arda Kayhan, MD; Xiaobing Fan, PhD; Aytekin Oto, MD. Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Prostate Cancer. Top Magn Reson Imaging, Vol. 20(2): pp.105-112, April 2009.

Aytekin Oto, MD; Yulei Jiang, PhD; Maria Tretiakova, MD; Cheng Yang, PhD; Tatjana Antic, MD; Farid Dahi, MD; Arieh L. Shalhav, MD; Gregory Karczmar,PhD; Walter M. Stadler, MD. Differentiation of central gland prostate cancer from benign prostatic hyperplasia using Diffusion weighted and dynamic contrast enhanced MR imaging. Presented at RSNA 2009.

Aytekin Oto, MD; Yulei Jiang, PhD; Maria Tretiakova, MD; Cheng Yang, PhD; Tatjana Antic, MD; Farid Dahi, MD; Arieh L. Shalhav, MD; Gregory Karczmar,PhD; Walter M. Stadler, MD. Differentiation of central gland prostate cancer from benign prostatic hyperplasia using Diffusion weighted and dynamic contrast enhanced MR imaging. Accepted for publication by Radiology.

McDannold N, Ziso H, Assif B, Hananel A, Vykhodtseva N, Gretton P, Pilatou M, Haker S, Tempany C.
MRI-guided focused ultrasound (MRgFUS) system for thermal ablation of prostate cancer: Pre-clinical evaluation in canines. Submitted to the International Society of Magnetic Resonance in Medicine 2009.

McDannold N, Ziso H, Assif B, Hananel A, Vykhodtseva N, Gretton P, Pilatou M, Tempany C. Pre-clinical evaluation of an MRI-guided transrectal focused ultrasound system for thermal ablation of prostate cancer in canines. To be presented at SPIE Photonics West, San Jose, CA, January 2009.

Ying Chen, et.al. A low Molecular weight PSMA=based fluorescent imaging for cancer. Biochemical and Biophysical Research Communications. December 2009, doi:10.10.16/j.bbrc2009.10.017, pp 1-6.

Chen, Y., Foss, C.A., Byun, Y., Nimmagadda, S., Pullambhatla, M., Fox, J.J., Castanares, M., Lupold, S.E., Babich, J.W., Mease, R.C., and Pomper, M.G. (2008). Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J Med Chem 51, 7933-7943.

Kimberly A. Kelly, Sunita R. Setlur, Robert Ross, Rajesh Anbazhagan, Peter Waterman, Mark A. Rubin, and Ralph Weissleder. Detection of Early Prostate Cancer Using a Hepsin-Targeted Imaging Agent. Cancer Research; 68: (7) April 1, 2008.

Mease RC, Dusich CL, Foss CA, Ravert HT, Dannals RF, Seidel J, Prideaux A, Fox JJ, Sgouros G, Kozikowski AP, Pomper MG. Synthesis and in vivo evaluation of N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Imaging, Diagnosis, Prognosis, 2008.

Mease, R.C., Dusich, C.L., Foss, C.A., Ravert, H.T., Dannals, R.F., Seidel, J., Prideaux, A., Fox, J.J., Sgouros, G., Kozikowski, A.P., and Pomper, M.G. (2008). N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res 14, 3036-3043.

Mathews, W. B., Foss, C. A., Stoermer, D., Ravert, H. T., Dannals, R. F., Henke, B. R., et al. 2005. Synthesis and biodistribution of [11C]GW7845, a positron-emitting agonist for PPARg. J. Nucl. Med. 46:1719-1726.

Banerjee, S.R., Foss, C.A., Castanares, M., Mease, R.C., Byun, Y., Fox, J.J., Hilton, J., Lupold, S.E., Kozikowski, A.P., and Pomper, M.G. (2008). Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem 51, 4504-4517.

Bettegowda, C., Foss, C. A., Cheong, I., Wang, Y., Diaz, L., Agrawal, N., Fox, J., Dick, J., Dang, L. H., Zhou, S., Kinzler, K. W., Vogelstein, B. & Pomper, M. G. (2005). Imaging bacterial infections with radiolabeled 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodouracil. Proc Natl Acad Sci U S A 102, 1145-50.

Byun, Y., Mease, R.C., Babich, J.W., and Pomper, M.G. (2008). Recent Development of Therapeutic and Diagnositc Agents Targeting Glutamate Carboxypeptidase II (GCPII), ed. C. Supran, Hoboken, NJ: John Wiley & Sons, In Press.

Chandran, S.S., Banerjee, S.R., Mease, R.C., Pomper, M.G., and Denmeade, S.R. (2008). Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA). Cancer Biol Ther 7, 974-982.

Chen, Y., Foss, C.A., Byun, Y., Nimmagadda, S., Pullambhatla, M., Fox, J.J., Castanares, M., Lupold, S.E., Babich, J.W., Mease, R.C., and Pomper, M.G. (2008). Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J Med Chem 51, 7933-7943.

Foss, C. A., Mease, R. C., Fan, H., Wang, Y., Ravert, H. T., Dannals, R. F., et al. 2005. Radiolabeled small molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin. Cancer Res. 11:4022-4028.

Kim DY, Schnall MD, Rosen MA, Connick T: Prostate MR imaging at 3T with a longitudinal array endorectal surface coil and phased array body coil. J Magn Reson Imaging 27(6): 1327-1330, 2008.

Tailor D, Rosen MConnick T, Charagundla S, Siegelman E, David K: Evaluation of Ultra High Resolution Prostate MRI at 3 Tesla with a Custom Dual Loop Endorectal Coil (Abstract) Radiological Society of North America 2007.

Gessman R, Tempany CM, and McDannold N. Predicted prostate cooling from a water cooled focused ultrasound rectal probe utilizing MRI dynamic contrast enhanced perfusion measurements. RSNA 2007.

Christopher A. Warlick, Martin G. Pomper, William B. Isaacs, Angelo M. DeMarzo, Ronald Rodriguez. Alpha-Methylacyl-CoA Racemase (AMACR)-based molecular imaging of prostate cancer. J Urology 175 (4 supp): 501. 2006. Platform Presentation AUA 2006.

R.C. Mease, C. Dusich, C.A. Foss, H.T. Ravert, R. F. Dannals, J. Seidel, J. Fox, A.P. Kozikowski and G. Pomper. Synthesis of N-[N-[(S)-1-3-Dicarboxypropyl] carbamoyl]-4-[18F]fluorobenzyl-L-Cysteine, [18F]DCFBC, its biodistribution and use in imaging prostate cancer xenografts. Society of Nuclear Medicine, 2006 [featured in the radiopharmaceutical chemistry “highlights” symposium.]

Majumder PK and Sellers WR Akt regulated pathways in prostate cancer. Oncogene 2005 Nov 14; 24(50):7465-74.

Majumder PK, Berger  R, O’Connell F, Baek WK, Xu Q, Bikoff  R, Herman P,  Wang S, Ellwood-Yen K, Wu H, Sawyers CL, Hahn WC, Loda M, Sellers WR. A prostatic intraepithelial neoplasia-dependent p27kip1 checkpoint inhibits cell proliferation and cancer progression. Cancer Cell. 2008 Aug 12;14(2):146-55.

Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA, Sellers WR. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med. 2004 Jun;10(6):594-601. Epub 2004 May 23.

Kung AL, Zabludoff SD, France DS, Freedman SJ, Tanner EA, Vieira A, Cornell-Kennon S, Lee J, Wang B, Wang J, Memmert K, Naegeli HU, Petersen F, Eck MJ, Bair KW, Wood AW, Livingston DM. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell. 2004 July 6(1): 33-43.

Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Libermann TA, Garcia-Echeverria C, Pearson MA, Hofmann F, Anderson KC,  Kung AL. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell. 2004, Mar. 5(3): 221-30.

Berger R, Febbo PG, Majumder PK, Zhao JJ, Mukherjee S, Signoretti S, Campbell KT, Sellers WR, Roberts TM, Loda M, Golub TR, Hahn WC. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res. 2004, Dec 15; 64(24): 8867-75.

Carroll PR, Chan JM, D'Amico AV, Gelmann EP, Iversen P, Klotz L, Nelson JB, Nelson PS, Nelson WG, Oh WK, Rosen N, Rubin MA, Sandler H, Sellers WR, Smith MR, Xu J, McMann MC, Kantoff PW. Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment. J Urol. 2004 Nov;172 (5 Pt 2):S3-5.

Walensky LD, Kung AL, Escher I, Malia TJ, Barbuto S, Wright RD, Wagner G, Verdine GL, Korsmeyer SJ Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix.
Science. 2004 Sept. 3;305(5689):1466-70.

Optimizing the probe geometry of elastic scattering spectroscopy for the diagnosis of prostate cancer,” O. M. A'amar, M.S. Hirsch, I.J. Bigio, Digest OSA Meetings on Biomedical Optics, Miami, (April 2004).

Optical Spectroscopy for the Management of Cancer Treatment, Irving J Bigio, Proc. Inter-Institute Workshop on Optical Diagnostic Imaging from Bench to Bedside, NIH  (Sept. 2004).

Elastic scattering spectroscopy for detection of prostate cancer: preliminary feasibility study, Irving J. Bigio, Ousama A’amar and Michelle S. Hirsch, Proc. SPIE 4151 (2003).

2004-The First International PTEN meeting, Scottsdale, Arizona, invited speaker, “Therapeutic targeting of the PI3K/PTEN/AKT pathway.

2004-The InterSPORE Prostate meeting, Chicago, IL, invited speaker, “The analysis of the prostate cancer genome using high-density single-nucleotide polymorphism arrays.”

2004-Molecular Imaging Think Thank, Bethesda, MD. Session chair and invited speaker. “The medical oncology perspective”.

2004-Protein Kinases and Cancer:  The Promise of Molecular-Based Therapies, Tahoe City, California. Session Chair and invited speaker. “Oncogenic signaling through the PTEN/PI3K/Akt pathway.

2004-EGFR Summit, Sunny Isle Beach, FL, invited speaker. “Therapeutic targeting of the PI3K/PTEN/AKT pathway”

2004-University of Rochester, Rochester, NY, invited speaker, “Therapeutic targeting of the PI3K/PTEN/AKT pathway”

2004-AACR Annual Meeting, Orlando, FL “Therapeutic targeting of the PTEN/PI3K/Akt pathway.” Invited Speaker.

2004-Exelixis Pharmaceuticals. San Mateo, CA. PTEN Summit Meeting. “Oncogenic Signaling through the PTEN/PI3K/AKT pathway”. Invited speaker.

2004-Amgen Pharmaceuticals. Thousand Oaks, CA. “Therapeutic targeting of the PTEN/PI3K/AKT pathway.” Invited speaker

2004-Karolinska Institute. Stockholm. Sweden. “Towards a understanding of the somatic genetics of prostate cancer.” Invited speaker.

2004-Instituto Juan March. Madrid, Spain. Symposia on mTOR and growth regulation. “Therapeutic targeting of the PI3K/PTEN/AKT pathway”. Invited speaker.

2004-University of Navarro. Pamplona, Spain. “Therapeutic targeting of the PI3K/PTEN/AKT pathway”. Invited speaker.

2004- Institute for Advance Studies, Princeton, NJ. “Somatic genetic alterations in prostate cancer.” Invited speaker.

2004-Meeting on Protein Kinases, Boston, MA. “Mutations in EGFR predict sensitivity to EGFR inhibition”. Invited Speaker.

2004-Millenium Pharmaceuticals. “Therapeutic targeting of the PI3K/PTEN/AKT pathway”. Invited Speaker.

2004-4th International Symposium on Translational Research in Oncology. Dublin, Ireland. “Recent concepts in defining EGFR small molecule inhibition sensitivity.” Invited Speaker.

2004-Emory University Medical School. “Therapeutic targeting of the PI3K/PTEN/AKT pathway”. Invited Speaker.

2005-Memorial Sloan Kettering Cancer Center. Cell Biology Seminar series. “Linking Somatic Genetic Alterations to Therapeutics”. New York, NY. Invited Speaker.

2005-4th International Symposium on Genitourinary Cancers. “Towards an understanding of the somatic genetic basis of prostate cancer.” Los Angeles, CA. Invited Speaker.

2005-UCLA Molecular and Medical Pharmacology Seminar Series. “Linking Somatic Genetic Alterations to Therapeutics”. Los Angeles, CA. Invited Speaker.

2005-UCLA Genitourinary Cancer Seminar Series. “Modeling Akt activation in the murine prostate.” Los Angeles, CA. Invited Speaker.

2005-NCI Biomarkers Think Tank. Houston, TX. Session Chair.

2005-RAD001 Think Tank. Novartis Pharmaceuticals. New York, NY. Invited Speaker

2005-Univ. of Pennsylvania Medical School. Cancer biology Seminar Series. “Linking Somatic Genetic Alterations to Therapeutics. Philadelphia, PA. Invited Speaker.

2005-American Association for Cancer Research Annual Meeting. Educational Session. “New Genomic Technologies”. Anaheim, CA. Session Chair and Speaker.

2005-American Association for Cancer Research Annual Meeting. Mini-symposium. “Kinase therapeutics”. Anaheim, CA. Session Co-Chair and Speaker.

2005-Vanderbilt Ingram Cancer Center. “Linking Somatic Alterations in Cancer to Therapeutics; EGFR & MITF”. Nashville, TN. Invited Speaker.

2005-Fourth Annual EGFR Summit. “Transgenic models: PTEN expressing tumors”. Boca Raton, FL. Faculty Member and Invited Speaker.

2005-Cold Spring Harbor Laboratories 70th Symposium “Molecular Therapeutics”. “Linking Somatic Genetic Alterations in Cancer to Therapeutics”. Cold Spring Harbor, New York. Invited Speaker.

2005-Leading Experts Advising on Development Summit. “Exploring the P13K/AKT Pathway”. Rome, Italy. Plenary Session and Invited Speaker.

2005-Era of Hope –DOD Breast Cancer Research Program Meeting. Philadelphia PA. Plenary Speaker.

2005-17th Pezcoller Symposiums. Trento, Italy. Session I. Co-Chair, Invited Speaker.

2005-Merck Oncology Retreat. “Linking Somatics Genetics to Therapeutics”. Seattle, WA. Invited Speaker.

2005-American Association for Cancer Research. “Molecular Biology in Clinical Oncology”, “Toward a Systematic Understanding of Somatic Cancer Genetics”. Aspen, CO. Faculty member.

2005-Genetech, ”Linking Somatic Alterations in Cancer to Therapeutics”. San Francisco, CA. Invited Speaker.